Symbicort Turbuhaler 60md: Advanced Control for Asthma and COPD
Symbicort
| Product dosage: 100 mcg + 6 mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $46.00 | $46.00 (0%) | 🛒 Add to cart |
| 2 | $36.50 | $92.00 $73.00 (21%) | 🛒 Add to cart |
| 3 | $32.00
Best per inhaler | $138.00 $96.00 (30%) | 🛒 Add to cart |
| Product dosage: 200 mcg + 6 mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $50.00 | $50.00 (0%) | 🛒 Add to cart |
| 2 | $45.50 | $100.00 $91.00 (9%) | 🛒 Add to cart |
| 3 | $41.00
Best per inhaler | $150.00 $123.00 (18%) | 🛒 Add to cart |
| Product dosage: 400 mcg + 6 mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $55.00 | $55.00 (0%) | 🛒 Add to cart |
| 2 | $50.00 | $110.00 $100.00 (9%) | 🛒 Add to cart |
| 3 | $44.00
Best per inhaler | $165.00 $132.00 (20%) | 🛒 Add to cart |
Synonyms | |||
Symbicort Turbuhaler 60md is a combination maintenance inhaler designed for the long-term management of asthma and chronic obstructive pulmonary disease (COPD). It contains two active ingredients: budesonide, an inhaled corticosteroid that reduces airway inflammation, and formoterol, a long-acting beta2-agonist that relaxes airway muscles. This dual-action formulation provides both anti-inflammatory and bronchodilatory effects, offering comprehensive control of respiratory symptoms. The Turbuhaler device ensures efficient and consistent drug delivery to the lungs with each actuation, supporting improved pulmonary function and quality of life.
Features
- Contains budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg per inhalation
- Delivered via the Turbuhaler dry powder inhaler device
- Provides 60 metered doses per inhaler
- Combines an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA)
- Requires no shaking or priming before use
- Features a dose counter to track remaining medication
Benefits
- Reduces frequency and severity of asthma exacerbations
- Improves lung function and exercise tolerance in COPD patients
- Provides 24-hour symptom control with twice-daily dosing
- Minimizes the need for rescue inhaler use
- Helps maintain open airways and reduce inflammation long-term
- Supports overall improvement in quality of life for respiratory patients
Common use
Symbicort Turbuhaler 60md is indicated for the maintenance treatment of asthma in patients aged 18 years and older where a combination product is appropriate. It is also approved for the maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. For asthma management, it is typically prescribed when inhaled corticosteroids alone provide inadequate control. In COPD, it is used to improve symptoms and reduce exacerbations in patients with a history of repeated flare-ups.
Dosage and direction
For asthma maintenance: The recommended dose is 2 inhalations twice daily (morning and evening). For COPD: The recommended dose is 2 inhalations twice daily. The maximum recommended dose is 4 inhalations twice daily. Patients should rinse their mouth with water after each use to reduce the risk of oral candidiasis. The Turbuhaler should be held upright during loading and administration. Twist the grip fully in one direction and then back until it clicks to load a dose. Breathe out gently away from the mouthpiece, place lips firmly around it, and inhale deeply and forcefully. Do not exhale into the device.
Precautions
Patients should be monitored for increased use of short-acting beta2-agonists, as this may indicate deteriorating asthma control. Systemic effects of corticosteroids may occur, particularly at high doses over prolonged periods, including adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract, and glaucoma. There is an increased risk of pneumonia in patients with COPD. Patients should be advised to seek medical attention if short-acting reliever treatment becomes less effective or they need more inhalations than usual. Paradoxical bronchospasm may occur—if this happens, treatment should be discontinued immediately.
Contraindications
Hypersensitivity to budesonide, formoterol, or any excipients. Not indicated for the relief of acute bronchospasm. Should not be used in patients with significantly worsening or acutely deteriorating asthma, which is a potentially life-threatening condition. Not recommended for patients with untreated fungal, bacterial, or tubercular respiratory infections. Contraindicated in patients with known or suspected pheochromocytoma due to risk of severe hypertension. Use with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.
Possible side effects
Common side effects (≥1/100 to <1/10) include: headache, tremor, palpitations, oropharyngeal candidiasis, hoarseness/dysphonia, and cough. Uncommon side effects (≥1/1,000 to <1/100) may include: tachycardia, muscle cramps, anxiety, nausea, dizziness, sleep disturbances, and skin reactions. Rare side effects (≥1/10,000 to <1/1,000) include: angioedema, bronchospasm, hypokalemia, hyperglycemia, and systemic corticosteroid effects. Very rare side effects (<1/10,000) may include: cardiac arrhythmias, psychiatric symptoms including behavioral changes, and vision disorders.
Drug interaction
Beta-blockers may weaken the effect of formoterol and may produce severe bronchospasm in patients with asthma. Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antihistamines, MAOIs, and TCAs may prolong the QTc interval and increase the risk of ventricular arrhythmias. Concomitant administration with other beta-adrenergic drugs may potentiate the sympathetic effects of formoterol. Ketoconazole and other potent CYP3A4 inhibitors may increase plasma levels of budesonide. The hypokalemic effect of formoterol may be potentiated by xanthine derivatives, steroids, and diuretics.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose. In that case, skip the missed dose and continue with the regular dosing schedule. Do not take a double dose to make up for a missed one. Patients should be advised to maintain a consistent dosing schedule to ensure optimal control of their respiratory condition.
Overdose
Overdose may lead to symptoms consistent with beta2-agonist overdose, including tachycardia, tremor, headache, muscle cramps, palpitations, nausea, dizziness, fatigue, malaise, hypokalemia, hyperglycemia, and metabolic acidosis. Cardiac arrest may occur. In case of overdose, symptomatic treatment is recommended. The use of cardioselective beta-blockers may be considered but with extreme caution in patients with asthma due to risk of bronchospasm. There is no specific antidote. Medical attention should be sought immediately.
Storage
Store at room temperature (15-30°C) in a dry place. Keep in the original container with the lid tightly closed to protect from moisture. Do not store in bathrooms or near sinks. Discard 3 months after opening or when the dose counter reads “0,” whichever comes first. Do not puncture or incinerate even when empty. Keep out of reach of children and pets.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting, changing, or stopping any medication. Individual patient needs may vary, and proper diagnosis and treatment planning should be conducted under medical supervision. The prescribing physician should be informed of all medical conditions and concurrent medications.
Reviews
Clinical studies demonstrate that Symbicort Turbuhaler significantly improves lung function parameters (FEV1) compared to monotherapy components alone. In asthma patients, it reduces exacerbation rates by approximately 40-50% compared to budesonide alone. COPD studies show a 30-35% reduction in moderate-to-severe exacerbations. Patient satisfaction surveys indicate high scores for device usability and symptom control. Real-world evidence supports maintained efficacy and safety profile over long-term use when prescribed appropriately.